Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Antiproliferative agents and protein farnesyltransferase inhibitors designed at RPR

Sep. 8, 1999

Licensing opportunity from NIH: novel acyltriazene antitumor agents

Sep. 8, 1999

Cyclic peptide represents new lead for tumor-targeting anticancer therapies

Sep. 7, 1999

Schering-Plough and British Biotech to develop MMPIs for treatment of cancer

Sep. 7, 1999

UroGenesys announces U.S. patent for PSA promoter sequences

Sep. 7, 1999

New protein farnesyltransferase inhibitors in the AstraZeneca pipeline

Sep. 6, 1999

3-D discloses inhibitors of trypsin-like serine proteases

Sep. 6, 1999

Promising results achieved in phase II study of thalidomide in multiple myeloma

Sep. 6, 1999

Synthesis and mechanism of action of a natural compound acting on a previously undefined target

Sep. 3, 1999

Potent protein farnesyltransferase inhibitors emerge from Parke-Davis program

Sep. 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...